Option Care Health Inc

Option Care Health Inc(OPCH)の株式分析

$31.200

-0.019 (-0.06%)終値時点

Loading chart…
高値
31.350
始値
31.240
出来高加重平均価格
31.24
出来高
2.85M
時価総額
4.86B
安値
31.175
売買代金
88.95M
EV/EBITDA(TTM)
13.29

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.

optioncarehealth.com

AI分析 of Option Care Health Inc (OPCH)

中立

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

バリュエーション指標

Option Care Health Inc(OPCH)の現在の予想PERは11.22で、5年平均は24.85です。

予想PER

割安
5年平均 P/E
24.85
現在のP/E
11.22
割高
31.75
割安
17.95

予想EV/EBITDA

適正
5年平均 EV/EBITDA
14.10
現在のEV/EBITDA
13.29
割高
17.21
割安
11.00

予想PSR

割安
5年平均 P/S
1.06
現在のP/S
0.76
割高
1.32
割安
0.79

Alphio AI による OPCH の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%OPCH

$38.45

シナリオ価格

基

基本

基本 · 50%OPCH

$31.36

シナリオ価格

弱

弱気

弱気 · 25%OPCH

$30.06

シナリオ価格

OPCH を保有するクジラ

S

Southpoint Capital Advisors LP

+ を保有OPCH

+3.71%

3か月リターン

S

Staley Capital Advisers, Inc.

+ を保有OPCH

+2.00%

3か月リターン

D

Durable Capital Partners, LP

+ を保有OPCH

-5.68%

3か月リターン

イベントタイムライン

2026-10-07 (ET)

08:00:00

Barrington Analyst Downgrades Option Care Health to Market Perform

2026-10-06 (ET)

16:30:00

McKesson and CD&R Agree to Acquire Option Care Health for $32.05 per Share

12:30:00

Option Care Health Shares Rise 32.9% to $31.05

12:00:00

Major Averages Rise for Second Day Amid Treasury Yield Retreat

10:30:00

Option Care Health Stock Rises 32.9% to $31.05

ニュース

OPCH のよくある質問 — Alphio AI が回答

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める